Laurence Nore

EVP Business Development & Operations at IgGenix

Presenter

IgGenix Inc is a US-based clinical-stage antibody therapeutics company spun out of Stanford University focused on the intersection of IgE in health and disease, with the vision to build the next frontier in I&I. Our unique technology platform uses single-cell transcriptomics to isolate very rare IgE producing B cells from individuals with conditions of interest. We are currently developing high affinity mAbs for food allergies as well as other IgE-mediated autoimmune diseases. Our lead program in peanut allergy is in the clinic and we expect results from this proof-of-mechanism trial in the second half of 2025, significantly de-risking this program, and the pipeline. Xolair, the first biologic to be approved in food allergy in the US in February, is performing strongly, with ~30,000 patients treated in only 7 months, demonstrating the blockbuster potential of the food allergy market. Globally the food allergy prevalence is estimated at 220 Million individuals and is growing. Our preclinical pipeline includes programs in shellfish and cashew/pistachio allergies. In addition we have initiated projects to discover novel targets and therapeutics in Atopic Dermatitis. Since inception, we have raised more than $60M from VCs such as Khosla Ventures, Alexandria Venture Investments and SBI, as well as Eli Lilly & Co, and will initiate discussions for our Series C round by the middle of 2025.